Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction

Area of Science:

• Nephrology
• Biomarker Research
• Peritoneal Dialysis

Background:

• Peritoneal dialysis (PD) is associated with progressive peritoneal injury over time.
• Matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) are key biomarkers of this injury.
• Understanding these biomarkers' trends and predictive capacity is crucial for PD patient management.

Purpose of the Study:

• To track trends of MMP-2 and TIMP-1 in incident PD patients.
• To assess MMP-2's ability to predict peritoneal solute transport rate (PSTR) and peritonitis.
• To evaluate the impact of neutral pH, low glucose degradation product (GDP) PD solutions on these outcomes.

Main Methods:

• Analysis of dialysate samples from 178 participants in the balANZ trial.
• Utilized multilevel linear regression for PSTR and multilevel Poisson regression for peritonitis prediction.
• Investigated the association between MMP-2, TIMP-1, PSTR, peritonitis, and PD solution type.

Main Results:

• Dialysate MMP-2 and TIMP-1 concentrations significantly increased with longer PD duration.
• Higher MMP-2 levels correlated with increased PSTR and a higher risk of peritonitis.
• Biocompatible PD solutions did not alter MMP-2/TIMP-1 levels but reduced PSTR and peritonitis risk compared to standard solutions.

Conclusions:

• MMP-2 and TIMP-1 are reliable indicators of peritoneal injury progression in PD patients.
• Elevated MMP-2 levels serve as a predictive marker for adverse patient outcomes, including faster PSTR and peritonitis.
• Biocompatible solutions offer a protective effect against PD-related complications, independent of MMP-2/TIMP-1 levels.